Association of Denture Use With Sleep-Disordered Breathing Among Older Adults

2006 ◽  
Vol 2006 ◽  
pp. 222
Author(s):  
B.A. Phillips
Author(s):  
Jesse K Siegel ◽  
Xiandao Yuan ◽  
Kristen E Wroblewski ◽  
Martha K McClintock ◽  
Jayant M Pinto

Abstract Background Sleep-disordered breathing (SDB) is a common, underdiagnosed condition in older adults with major health consequences, including disrupted central nervous system functioning. Whether SDB may affect sensory function is unclear. We sought to address this question by comparing 2 forms of olfactory testing which measure peripheral and central olfactory processing. Methods We assessed SDB (survey-reported snoring frequency, nighttime apneic events, or diagnosis of sleep apnea) in the National Social Life, Health, and Aging Project, a nationally representative sample of older U.S. adults. Odor sensitivity (peripheral) and odor identification (central) were assessed with validated instruments. Logistic regression was used to test the relationship between SDB and olfaction, accounting for relevant covariates, including demographics, cognition, and comorbidity. Results Twenty-nine percent of older U.S. adults reported symptoms of SDB (apneic events or nightly snoring). Of these, only 32% had been diagnosed with sleep apnea. Older adults with SDB (those who reported symptoms or have been diagnosed with sleep apnea) were significantly more likely to have impaired odor identification (odds ratio 2.13, 95% confidence interval 1.19–3.83, p = .012) in analyses that accounted for age, gender, race/ethnicity, education, cognition, comorbidities (including depression), and body mass index. Presence of SDB was not associated with impaired odor sensitivity (odds ratio 1.03, 95% confidence interval 0.75–1.43, p = .84). Conclusion SDB is highly prevalent but underdiagnosed in older U.S. adults and is associated with impaired odor identification but not odor sensitivity. These data support the concept that SDB affects pathways in the central nervous system which involve chemosensory processing.


2017 ◽  
Vol 114 (38) ◽  
pp. 10250-10255 ◽  
Author(s):  
Ana C. Pereira ◽  
Xiangling Mao ◽  
Caroline S. Jiang ◽  
Guoxin Kang ◽  
Sara Milrad ◽  
...  

Sleep-disordered breathing (SDB) is a common disorder in aging that is associated with cognitive decline, including significant executive dysfunction, for which the neurobiological underpinnings remain poorly understood. Using proton magnetic resonance spectroscopy (1H MRS), this study assessed whether dysregulation of the homeostatic balance of the major inhibitory and excitatory amino acid neurotransmitter systems of γ-aminobutyric acid (GABA) and glutamate, respectively, play a role in SDB. Levels of GABA and those of the combined resonances of glutamate and glutamine (Glx), were measured by 1H MRS in the left dorsolateral prefrontal cortex (l-DLPFC) and bilateral hippocampal regions of 19 older adults (age ± SD: 66.1 ± 1.9 years) with moderate to severe SDB, defined as having an Apnea–Hypopnea Index (AHI) greater than 15 as assessed by polysomnography, and in 14 older adults (age ± SD: 62.3 ± 1.3 years) without SDB (AHI < 5). In subjects with SDB, levels of l-DLPFC GABA, but not Glx, were significantly lower than in control subjects (P< 0.0002). Additionally, there was a negative correlation between l-DLPFC GABA levels, but not Glx, and SDB severity by AHI (r= -0.68,P< 0.0001), and a positive correlation between l-DLPFC GABA levels, but not Glx, and minimal oxygen saturation during sleep (r= 0.62,P= 0.0005). By contrast, no group differences or oxygenation associations were found for levels of GABA or Glx in right or left hippocampal region. These findings are interpreted in terms of a pathophysiological model of SDB in which hypoxia-mediated inhibitory neurotransmission deficit in DLPFC could lead to hyperexcitability and, potentially neuronal dysfunction and cognitive decline.


SLEEP ◽  
2004 ◽  
Vol 27 (3) ◽  
pp. 474-479 ◽  
Author(s):  
Jingzhong Ding ◽  
F. Javier Nieto ◽  
Norman J. Beauchamp ◽  
Tamara B. Harris ◽  
John A. Robbins ◽  
...  

SLEEP ◽  
2011 ◽  
Vol 34 (4) ◽  
pp. 435-442 ◽  
Author(s):  
Nalaka S. Gooneratne ◽  
Kathy C. Richards ◽  
Marshall Joffe ◽  
Regina W. Lam ◽  
Fran Pack ◽  
...  

Author(s):  
Molly E. Zimmerman ◽  
Mark S. Aloia

Efforts aimed toward alleviating senescence have intensified as older adults occupy an increasing proportion of the population. Cognitive abilities become compromised with advancing age, with a vast heterogeneity of presentations, ranging from occasional word-finding difficulties to dementia. The role of sleep disordered breathing (SDB) in moderating or mediating age-related cognitive decline is particularly relevant given its potential reversibility in response to positive airway pressure (PAP) therapies. Establishment of SDB as a significant contributor to the development of dementia and cognitive dysfunction among the elderly has immense public health relevance, underscoring the importance of its early identification and treatment. Although several studies have examined the effect of PAP on cognitive function in older adults with SDB, additional prospective randomized clinical trials are needed. This chapter reviews the literature on SDB and cognition among the elderly as well as cognitive changes in response to PAP. Considerations for future research are also discussed.


2016 ◽  
Vol 78 (5) ◽  
pp. 629-639 ◽  
Author(s):  
Constance H. Fung ◽  
Jennifer L. Martin ◽  
Karen Josephson ◽  
Lavinia Fiorentino ◽  
Joseph M. Dzierzewski ◽  
...  

2001 ◽  
Vol 2 (6) ◽  
pp. 511-516 ◽  
Author(s):  
Sonia Ancoli-Israel ◽  
Philip Gehrman ◽  
Daniel F. Kripke ◽  
Carl Stepnowsky ◽  
William Mason ◽  
...  

2009 ◽  
Vol 1 ◽  
pp. CMT.S1940
Author(s):  
Natalie D. Dautovich ◽  
Jacob M. Williams ◽  
Christina S. McCrae

The present paper presents a review of the literature examining the efficacy of eszopiclone for treating insomnia. The purpose of the paper was to evaluate both the statistical and clinical efficacy of eszopiclone for treating insomnia. Both subjective and objective assessments of insomnia were evaluated across various sleep variables. Additionally, the efficacy of eszopiclone for treating insomnia comorbid with other conditions (sleep disordered breathing, psychiatric diagnoses, peri/post-menopause, rheumatoid arthritis), transient insomnia, and across diverse samples (adults, older adults, and samples pooled by race) was reviewed. Finally, the impact of eszopiclone use on daytime functioning was examined.


Sign in / Sign up

Export Citation Format

Share Document